Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.

PURPOSE We assessed health related quality of life in patients with advanced renal cell carcinoma treated with nephrectomy and tumor infiltrating lymphocyte therapy in combination with interleukin-2. MATERIALS AND METHODS A total of 20 patients with advanced renal cell carcinoma who underwent nephrectomy and combination immunotherapy with tumor infiltrating lymphocytes and interleukin-2 completed a retrospective, cross-sectional health related quality of life instrument. Established reference populations with other chronic medical conditions, or breast, prostate or other cancers were used for comparison of health related quality of life scores. General health related quality of life was measured with a RAND 36-Item Health Survey 1.0. Cancer targeted quality of life was measured with the Cancer Rehabilitation Evaluation System-Short Form. Sociodemographic and co-morbidity variables were also collected. RESULTS General health related quality of life in patients treated with tumor infiltrating lymphocytes and interleukin-2 was significantly better than that in heart failure patients on 1 of 8 scales but significantly worse than in the general population on 6 of 8 scales. General health related quality of life in the former patients was also significantly worse than in those with hypertension on 5 of 8 scales and significantly worse than in diabetics on 2 scales. Cancer targeted health related quality of life in patients given immunotherapy was significantly better than in men with prostate cancer on 1 of 5 scales, significantly better than in women with breast cancer on 2 of 5 scales and significantly better than patients with other cancers (nonbreast and nonprostate) on 3 of 5 scales. CONCLUSIONS Patients undergoing nephrectomy and adjuvant tumor infiltrating lymphocytes plus interleukin-2 therapy for advanced renal cell carcinoma report better health related quality of life than those with other malignancies and better physical function than patients with congestive heart failure. However, health related quality of life is worse than in the general population and similar or worse than in patients with hypertension or type II diabetes. This surveyed population is selective and may represent the best responders among survivors of a highly toxic therapy. Nevertheless, quality and quantity of life should be addressed with patients when considering immunotherapy for metastatic kidney cancer.

[1]  R. Figlin,et al.  Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Figlin,et al.  The treatment of renal cell carcinoma with human leukocyte alpha-interferon. , 1983, The Journal of urology.

[3]  J. Quesada.  Biologic response modifiers in the therapy of metastatic renal cell carcinoma. , 1988, Seminars in oncology.

[4]  C. Moinpour,et al.  Quality of life end points in cancer clinical trials: review and recommendations. , 1989, Journal of the National Cancer Institute.

[5]  R. Figlin,et al.  Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma , 1993 .

[6]  R. Heinrich,et al.  Development of a comprehensive quality of life measurement tool: CARES. , 1990, Oncology.

[7]  M. Litwin.  Measuring health related quality of life in men with prostate cancer. , 1994, The Journal of urology.

[8]  J. E. Brazier,et al.  Validating the SF-36 health survey questionnaire: new outcome measure for primary care. , 1992, BMJ.

[9]  R. Deyo,et al.  Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life , 1989, Medical care.

[10]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[11]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[12]  S Greenfield,et al.  The Importance of Co-existent Disease in the Occurrence of Postoperative Complications and One-Year Recovery in Patients Undergoing Total Hip Replacement: Comorbidity and Outcomes After Hip Replacement , 1993, Medical care.

[13]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[14]  Tannock If.  Management of breast and prostate cancer: how does quality of life enter the equation? , 1990 .

[15]  D. Lamm,et al.  Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma , 1990, The Lancet.

[16]  P. Ganz,et al.  CAncer rehabilitation evaluation system–short form (CARES‐SF). A cancer specific rehabilitation and quality of life instrument , 1991, Cancer.

[17]  P. Ganz,et al.  Assessing the quality of life--a study in newly-diagnosed breast cancer patients. , 1990, Journal of clinical epidemiology.

[18]  A. Belldegrun,et al.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. , 1988, Cancer research.

[19]  William H. Rogers,et al.  Functional Status and Well-Being of Patients with Chronic Conditions , 1989 .

[20]  J. Quesada,et al.  Renal cell carcinoma: antitumor effects of leukocyte interferon. , 1983, Cancer research.

[21]  A. Stewart,et al.  Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. , 1989, JAMA.

[22]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[23]  M. Tattersall,et al.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.

[24]  I. Tannock.  Treating the patient, not just the cancer. , 1987, The New England journal of medicine.

[25]  R. Figlin,et al.  Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. , 1995, Seminars in oncology.